Marshall Wace
SRRA

Marshall Wace’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Marshall Wace’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-284,781
Closed -$9.13M – 4043
2022
Q1 		$9.13M Buy
+284,781
New +$8.17M 0.02% 938

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace's SRRA Position: Q2 2022 in Review

Marshall Wace sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 284,781 shares — an estimated $9.13M sold.

Marshall Wace first reported a position in SRRA in Q1 2022 and held it in 1 quarter. The position peaked at $9.13M in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

  • Marshall Wace reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Marshall Wace sold 284,781 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $9.13M.
  • Marshall Wace first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Marshall Wace's Sierra Oncology, Inc. Common Stock position peaked at $9.13M in Q1 2022.
  • 109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.